vs
安进（AMGN）与CRH PUBLIC LTD CO（CRH）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是CRH PUBLIC LTD CO的1.0倍（$9.9B vs $9.4B），安进净利率更高（13.5% vs 10.9%，领先2.6%），安进同比增速更快（8.6% vs 6.2%），过去两年CRH PUBLIC LTD CO的营收复合增速更高（20.1% vs 15.1%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
CRH是总部位于爱尔兰都柏林的知名建材供应商，主要生产骨料、水泥等建筑材料，同时制造预拌混凝土、沥青混凝土及基建部件，是北美地区规模最大的建材供应商之一，目前在北美、欧洲、澳大利亚、菲律宾等28个国家设有3816个运营网点。
AMGN vs CRH — 直观对比
营收规模更大
AMGN
是对方的1.0倍
$9.4B
营收增速更快
AMGN
高出2.4%
6.2%
净利率更高
AMGN
高出2.6%
10.9%
两年增速更快
CRH
近两年复合增速
15.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $9.4B |
| 净利润 | $1.3B | $1.0B |
| 毛利率 | 69.8% | 35.6% |
| 营业利润率 | 27.6% | 14.9% |
| 净利率 | 13.5% | 10.9% |
| 营收同比 | 8.6% | 6.2% |
| 净利润同比 | 112.6% | 45.8% |
| 每股收益（稀释后） | $2.45 | $1.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNCRH
| Q4 25 | $9.9B | $9.4B | ||
| Q3 25 | $9.6B | $11.1B | ||
| Q2 25 | $9.2B | $10.2B | ||
| Q1 25 | $8.1B | $6.8B | ||
| Q4 24 | $9.1B | $8.9B | ||
| Q3 24 | $8.5B | $10.5B | ||
| Q2 24 | $8.4B | $9.7B | ||
| Q1 24 | $7.4B | $6.5B |
净利润AMGNCRH
| Q4 25 | $1.3B | $1.0B | ||
| Q3 25 | $3.2B | $1.5B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.7B | $-94.0M | ||
| Q4 24 | $627.0M | $703.0M | ||
| Q3 24 | $2.8B | $1.4B | ||
| Q2 24 | $746.0M | $1.3B | ||
| Q1 24 | $-113.0M | $116.0M |
毛利率AMGNCRH
| Q4 25 | 69.8% | 35.6% | ||
| Q3 25 | 67.8% | 38.9% | ||
| Q2 25 | 67.2% | 39.4% | ||
| Q1 25 | 63.6% | 27.2% | ||
| Q4 24 | 65.7% | 35.6% | ||
| Q3 24 | 61.1% | 38.6% | ||
| Q2 24 | 61.4% | 38.1% | ||
| Q1 24 | 57.0% | 27.7% |
营业利润率AMGNCRH
| Q4 25 | 27.6% | 14.9% | ||
| Q3 25 | 26.4% | 18.8% | ||
| Q2 25 | 28.9% | 19.0% | ||
| Q1 25 | 14.5% | 0.3% | ||
| Q4 24 | 25.4% | 12.4% | ||
| Q3 24 | 24.1% | 18.7% | ||
| Q2 24 | 22.8% | 18.9% | ||
| Q1 24 | 13.3% | 0.4% |
净利率AMGNCRH
| Q4 25 | 13.5% | 10.9% | ||
| Q3 25 | 33.7% | 13.6% | ||
| Q2 25 | 15.6% | 12.9% | ||
| Q1 25 | 21.2% | -1.4% | ||
| Q4 24 | 6.9% | 7.9% | ||
| Q3 24 | 33.3% | 13.1% | ||
| Q2 24 | 8.9% | 13.4% | ||
| Q1 24 | -1.5% | 1.8% |
每股收益（稀释后）AMGNCRH
| Q4 25 | $2.45 | $1.51 | ||
| Q3 25 | $5.93 | $2.21 | ||
| Q2 25 | $2.65 | $1.94 | ||
| Q1 25 | $3.20 | $-0.15 | ||
| Q4 24 | $1.17 | $1.01 | ||
| Q3 24 | $5.22 | $1.97 | ||
| Q2 24 | $1.38 | $1.88 | ||
| Q1 24 | $-0.21 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $4.1B |
| 总债务越低越好 | $54.6B | $17.5B |
| 股东权益账面价值 | $8.7B | $24.0B |
| 总资产 | $90.6B | $58.3B |
| 负债/权益比越低杠杆越低 | 6.31× | 0.73× |
8季度趋势，按日历期对齐
现金及短期投资AMGNCRH
| Q4 25 | $9.1B | $4.1B | ||
| Q3 25 | $9.4B | $4.2B | ||
| Q2 25 | $8.0B | $2.9B | ||
| Q1 25 | $8.8B | $3.4B | ||
| Q4 24 | $12.0B | $3.7B | ||
| Q3 24 | $9.0B | $3.0B | ||
| Q2 24 | $9.3B | $3.1B | ||
| Q1 24 | $9.7B | $3.3B |
总债务AMGNCRH
| Q4 25 | $54.6B | $17.5B | ||
| Q3 25 | $54.6B | $18.6B | ||
| Q2 25 | $56.2B | $15.7B | ||
| Q1 25 | $57.4B | $15.6B | ||
| Q4 24 | $60.1B | $13.9B | ||
| Q3 24 | $60.4B | $13.7B | ||
| Q2 24 | $62.6B | $13.0B | ||
| Q1 24 | $64.0B | $12.6B |
股东权益AMGNCRH
| Q4 25 | $8.7B | $24.0B | ||
| Q3 25 | $9.6B | $23.3B | ||
| Q2 25 | $7.4B | $22.3B | ||
| Q1 25 | $6.2B | $21.1B | ||
| Q4 24 | $5.9B | $21.6B | ||
| Q3 24 | $7.5B | $21.9B | ||
| Q2 24 | $5.9B | $20.7B | ||
| Q1 24 | $5.0B | $20.0B |
总资产AMGNCRH
| Q4 25 | $90.6B | $58.3B | ||
| Q3 25 | $90.1B | $58.5B | ||
| Q2 25 | $87.9B | $54.0B | ||
| Q1 25 | $89.4B | $51.9B | ||
| Q4 24 | $91.8B | $50.6B | ||
| Q3 24 | $90.9B | $51.2B | ||
| Q2 24 | $90.9B | $48.1B | ||
| Q1 24 | $93.0B | $46.3B |
负债/权益比AMGNCRH
| Q4 25 | 6.31× | 0.73× | ||
| Q3 25 | 5.67× | 0.80× | ||
| Q2 25 | 7.57× | 0.70× | ||
| Q1 25 | 9.24× | 0.74× | ||
| Q4 24 | 10.23× | 0.64× | ||
| Q3 24 | 8.02× | 0.63× | ||
| Q2 24 | 10.57× | 0.63× | ||
| Q1 24 | 12.75× | 0.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $2.9B |
| 自由现金流经营现金流 - 资本支出 | $961.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 6.5% | — |
| 现金转化率经营现金流/净利润 | 1.20× | 2.84× |
| 过去12个月自由现金流最近4个季度 | $8.1B | — |
8季度趋势，按日历期对齐
经营现金流AMGNCRH
| Q4 25 | $1.6B | $2.9B | ||
| Q3 25 | $4.7B | $2.0B | ||
| Q2 25 | $2.3B | $1.4B | ||
| Q1 25 | $1.4B | $-659.0M | ||
| Q4 24 | $4.8B | $2.7B | ||
| Q3 24 | $3.6B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B | ||
| Q1 24 | $689.0M | $-712.0M |
自由现金流AMGNCRH
| Q4 25 | $961.0M | — | ||
| Q3 25 | $4.2B | — | ||
| Q2 25 | $1.9B | $723.0M | ||
| Q1 25 | $980.0M | $-1.3B | ||
| Q4 24 | $4.4B | $1.8B | ||
| Q3 24 | $3.3B | $981.0M | ||
| Q2 24 | $2.2B | $861.0M | ||
| Q1 24 | $459.0M | $-1.2B |
自由现金流率AMGNCRH
| Q4 25 | 9.7% | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 20.8% | 7.1% | ||
| Q1 25 | 12.0% | -19.3% | ||
| Q4 24 | 48.4% | 20.1% | ||
| Q3 24 | 39.0% | 9.3% | ||
| Q2 24 | 26.5% | 8.9% | ||
| Q1 24 | 6.2% | -18.6% |
资本支出强度AMGNCRH
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.0% | 6.4% | ||
| Q1 25 | 5.0% | 9.5% | ||
| Q4 24 | 4.1% | 10.6% | ||
| Q3 24 | 3.0% | 4.8% | ||
| Q2 24 | 2.8% | 6.5% | ||
| Q1 24 | 3.1% | 7.7% |
现金转化率AMGNCRH
| Q4 25 | 1.20× | 2.84× | ||
| Q3 25 | 1.46× | 1.32× | ||
| Q2 25 | 1.59× | 1.04× | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 7.61× | 3.88× | ||
| Q3 24 | 1.26× | 1.08× | ||
| Q2 24 | 3.30× | 1.14× | ||
| Q1 24 | — | -6.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
CRH
| Products | $7.1B | 76% |
| Essential Materials | $1.4B | 15% |
| Outdoor Living Solutions | $842.0M | 9% |
